Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670378 | 0.91 | KMT2A (0.40) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL2670267 | 0.90 | KMT2A (0.39) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL3977151 | 0.89 | KMT2A (0.41) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL3978371 | 0.88 | KMT2A (0.40) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL2670290 | 0.85 | KMT2A (0.35) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL3977830 | 0.82 | KMT2A (0.36) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL2670266 | 0.80 | KMT2A (0.40) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL2670120 | 0.79 | KMT2A (0.40) | KMT2AMAPK1HTTHSD11B1GAA | |
| SCHEMBL2670149 | 0.79 | KMT2A (0.38) | KMT2AHSD11B1CYP3A4CYP2C9 | |
| SCHEMBL4750234 | 0.78 | KMT2A (0.38) | KMT2AHSD11B1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8618094-B2 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| EP-2540715-A1 | Fused substituted aminopyrrolidine derivative | Daiichi Sankyo Company, Limited (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885HTT 4836/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885HTT 4836/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | KMT2A 2847/4885MAPK1 2614/4885HTT 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.